LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

Search

Merus NV

Gesloten

SectorGezondheidszorg

41.4 3.45

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

41.28

Max

41.75

Belangrijke statistieken

By Trading Economics

Inkomsten

-66M

-96M

Verkoop

17M

26M

EPS

-1.4

Winstmarge

-364.218

Werknemers

260

EBITDA

-88M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+114.75% upside

Dividenden

By Dow Jones

Volgende Winsten

30 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

302M

2.9B

Vorige openingsprijs

37.95

Vorige sluitingsprijs

41.4

Nieuwssentiment

By Acuity

48%

52%

155 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Merus NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mei 2025, 23:47 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

18 mei 2025, 23:40 UTC

Marktinformatie

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

18 mei 2025, 18:00 UTC

Winsten

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

18 mei 2025, 17:01 UTC

Top Nieuws

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

18 mei 2025, 16:20 UTC

Winsten

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

18 mei 2025, 12:09 UTC

Top Nieuws

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

17 mei 2025, 17:15 UTC

Top Nieuws

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 mei 2025, 09:30 UTC

Top Nieuws
Winsten

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 mei 2025, 08:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 mei 2025, 08:20 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

16 mei 2025, 23:18 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mei 2025, 22:30 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- Update

16 mei 2025, 21:56 UTC

Marktinformatie

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mei 2025, 21:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

16 mei 2025, 21:54 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mei 2025, 21:22 UTC

Marktinformatie

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mei 2025, 21:17 UTC

Marktinformatie

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mei 2025, 21:17 UTC

Top Nieuws

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mei 2025, 21:05 UTC

Marktinformatie

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mei 2025, 20:55 UTC

Acquisities, Fusies, Overnames

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mei 2025, 20:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

16 mei 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 mei 2025, 20:37 UTC

Top Nieuws

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mei 2025, 20:33 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mei 2025, 20:30 UTC

Acquisities, Fusies, Overnames

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mei 2025, 20:18 UTC

Top Nieuws

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mei 2025, 20:16 UTC

Top Nieuws

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mei 2025, 20:15 UTC

Winsten

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mei 2025, 20:11 UTC

Acquisities, Fusies, Overnames

Henry Schein: William K. Daniel Joins Board

16 mei 2025, 20:10 UTC

Acquisities, Fusies, Overnames

Henry Schein: Strategic Investment by KKR Completed

Peer Vergelijking

Prijswijziging

Merus NV Prognose

Koersdoel

By TipRanks

114.75% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 89.25 USD  114.75%

Hoogste 110 USD

Laagste 67 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merus NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Technische score

By Trading Central

39.445 / 44.36Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

155 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.